Semi-Solid Dosage Contract Manufacturing Market Size to Hit USD 56.50 Bn by 2034
Semi-Solid Dosage Contract Manufacturing Market Size and Growth
The global semi-solid dosage contract manufacturing market size was valued at USD 19.51 billion in 2024 and is predicted to hit around USD 56.50 billion by 2034, growing at a CAGR of 11.22%.
The semi-solid dosage contract manufacturing market is expanding as pharmaceutical and biotechnology companies seek cost-effective and specialized production solutions. Semi-solid formulations, including ointments, gels, and creams, play a crucial role in drug delivery for dermatology, pain relief, and wound care applications. The increasing adoption of contract manufacturing services is driven by the need for regulatory compliance, technical expertise, and improved production scalability.
Semi-Solid Dosage Contract Manufacturing Market Key Highlights
-
Asia Pacific emerged as the leading regional market, contributing over 33% in 2024.
-
North America is expected to grow at the highest CAGR of 10.67% in the forecast years.
-
The topical segment dominated the market, securing 50% of the total share in 2024.
-
The transdermal segment is poised for notable expansion in the upcoming years.
-
Creams represented the largest product category in 2024.
-
Large-sized companies held the most significant market share in 2024.
-
The medium and small-sized companies segment is projected to expand substantially.
-
Pharmaceutical companies stood as the leading end users in 2024.
-
Cosmeceutical companies are anticipated to witness considerable growth over the forecast period.
Market Scope
| Report Coverage | Details |
| Market Size by 2034 | USD 56.50 Billion |
| Market Size in 2025 | USD 21.70 Billion |
| Market Size in 2024 | USD 19.51 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 11.22% |
| Dominated Region | Asia Pacific |
| Fastest Growing Market | North America |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Type, Product, Company Size, End-use, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Market Dynamics
Market Drivers
The market is driven by the rising demand for topical drug formulations, growing outsourcing trends in the pharmaceutical industry, and continuous advancements in formulation science. The increasing focus on patient-friendly drug delivery methods, such as transdermal and mucosal applications, is further boosting market growth. Additionally, contract manufacturers provide cost efficiency and faster time-to-market, making them an attractive option for pharmaceutical firms.
Market Opportunities
Expanding R&D in drug formulation and the development of bio-based and sustainable excipients are creating new market opportunities. Increased regulatory approvals for topical and transdermal treatments, along with the rise in combination therapies, are further driving innovation in semi-solid dosage contract manufacturing. The growing pharmaceutical outsourcing trend in emerging economies presents additional business prospects for contract manufacturers.
Market Challenges
Strict regulatory requirements, formulation complexity, and the need for consistent quality control pose challenges for manufacturers. High initial costs for facility upgrades and compliance with Good Manufacturing Practices (GMP) add to the operational burden. Moreover, market competition is intense, requiring manufacturers to constantly innovate and optimize production capabilities.
Regional Insights
North America leads the market due to its strong pharmaceutical sector and demand for advanced drug delivery systems. Europe remains a key region, focusing on premium-quality contract manufacturing services and regulatory compliance. Meanwhile, Asia-Pacific is emerging as a major hub for pharmaceutical outsourcing, driven by lower production costs, expanding healthcare infrastructure, and increasing foreign investments in the sector.
Semi-Solid Dosage Contract Manufacturing Market Companies
- Lonza Group Ltd.
- Lubrizol Life Science
- Cambrex Corporation
- Contract Pharmaceuticals Limited
- Bora Pharmaceutical CDMO
- Ascendia Pharmaceuticals
- Pierre Fabre group
- Piramal Pharma Solutions
- DPT Laboratories, LTD
- MedPharm Ltd
- Catalent, Inc.
- Recipharm AB
- Aenova Group
- Almac Group
- Ajinomoto Bio-Pharma Services
Recent Developments
- In September 2023, HERMES PHARMA disclosed USD 27.44 million (€ 25 million) as an investment to improve its manufacturing processes. The financial investment will drive the company toward leading technological equipment that enables enhanced production, storage capacity, and operational excellence, matching the market need for user-friendly oral medication dosage.
- In March 2023, Adragos Pharma acquired the development unit of Clinigen known as Lamda Laboratories, enabling medicinal product development as well as regulatory affairs, including supply chain management expansion. Lamda’s team members with extensive sector knowledge will persist with developing complex products that target European, Japanese, and North American markets for multiple drug forms.
Segments Covered in the Report
By Type
- Topical
- Transdermal
- Oral
By Product
- Creams
- Ointments
- Gels
- Lotions
- Pastes
- Others
By Company Size
- Large Size Companies
- Medium and Small Size Companies
- Others
By End Use
- Pharmaceutical Companies
- Cosmeceutical Companies
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Also Read: U.S. Patient Engagement Solutions Market
Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/
